SCHEMBL3605081

SCHEMBL3605081

CS(=O)(=O)NCc1ccc([O])cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.61
KDM4E B2RXH2 2/20 0.51
POLB P06746 2/20 0.51
TSHR P16473 1/20 0.51
RECQL P46063 1/20 0.51
MEN1 O00255 2/20 0.45
CNR2 P34972 1/20 0.45
CA12 O43570 3/20 0.43
CA2 P00918 3/20 0.43
CA7 P43166 2/20 0.43
CA14 Q9ULX7 2/20 0.43
NAMPT P43490 1/20 0.43
CA1 P00915 2/20 0.42
CA9 Q16790 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
HTT P42858 2/20 0.41
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14852 0.83 KMT2A (0.61) KMT2AKDM4EPOLBTSHRRECQL
SCHEMBL4491485 0.83 KMT2A (0.61) KMT2AKDM4EPOLBTSHRRECQL
SCHEMBL552189 0.81 KMT2A (0.59) KMT2AKDM4EPOLBTSHRRECQL
SCHEMBL7230378 0.81 KMT2A (0.65) KMT2AKDM4EPOLBTSHRRECQL
SCHEMBL14862123 0.81 KMT2A (0.59) KMT2AKDM4EPOLBTSHRRECQL
SCHEMBL6338974 0.81 KMT2A (0.70) KMT2AKDM4EPOLBTSHRRECQL
SCHEMBL5314524 0.81 KMT2A (0.59) KMT2AKDM4EPOLBTSHRRECQL
SCHEMBL3599158 0.81 KMT2A (0.59) KMT2AKDM4EPOLBTSHRRECQL
SCHEMBL22497546 0.81 KMT2A (0.59) KMT2AKDM4EPOLBTSHRRECQL
SCHEMBL2100494 0.81 KMT2A (0.59) KMT2AKDM4EPOLBTSHRRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7754743-B2 Heteroarylcarbamoylbenzene derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-07-13 US disclosed
US-20090018056-A1 Heteroarylcarbamoylbenzene derivatives MSD K.K. (JP) 2009-01-15 US disclosed
US-7432287-B2 Heteroarylcarbamoylbenzene derivative BANYU PHARMECEUTICAL CO., LTD. (JP) 2008-10-07 US disclosed
US-20060167053-A1 Heteroarylcarbamoylbenzene derivative MSD K.K. (JP) 2006-07-27 US disclosed
EP-1600442-A1 HETEROARYLCARBAMOYLBENZENE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2005-11-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018056-A1 Heteroarylcarbamoylbenzene derivatives GCK, GCKR, KHK KMT2A 1536/4885KDM4E 800/4885POLB 1802/4885
US-20060167053-A1 Heteroarylcarbamoylbenzene derivative GCK, GCKR, GALK1 KMT2A 3162/4885KDM4E 2147/4885POLB 912/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.